Homepage |
首页 新闻动态 法律服务 数据服务 项目服务 投资环境 投资服务机构 经济开发区
Macro-Economy | Business Economy | Industrial Economy | Regional Economy

Home >News >Full article
Search
8 world top 500 biopharmaceutical companies located in Wuhan
2013/11/18 15:32:38 Source:hubei.gov.cn
The Wuhan National Bioindustry Base (Biolake), founded in Wuhan, central China’s Hubei Province for only 5 years, has become a gathering place of the well-known bio-pharmaceutical companies and research institutions at home and abroad.
 
Sanofi Pasteur, a world-known French vaccine company, signed cooperation agreement with China National Pharmaceutical Group and Wuhan East Lake Hi-tech Development Zone in France on Nov 25. It plans to co-create a production base in Biolake International Vaccine Park, with the aim of offering innovative technology and high-quality biological products worldwide.
 
Till now, eight out of the thirteen world top 500 biopharmaceutical companies have been located in Biolake, the number comes out front among the 26 Chinese bio-industry bases.
 
The famous companies in the Biolake are America’s Pfizer, Germany’s Bayer, Fresenius Kabi, Thermo Fisher, Honeywell and DuPont Pioneer
 
The person in charge of Pfizer (China) Research and Development Company said that Biolake’s talents, scientific research and environment attract them to situate the company, which is operated well and has over 400 staffs now.
 
Located at the Wuhan East Lake National Innovation Demonstration Area, the Wuhan National Bioindustry Base is the second key national industry base built by the Optics Valley of China in 2008 under the guidance of the concept of “100-billion-yuan industries”. With a start-up area of 15 square kilometers, Biolake focuses on building six major parks including Bio-innovation Park, Bio-pharma Park, Bio-agriculture Park, Bio-manufacturing Park, Medical Device Park and Medical Health Park, to create a new bioindustry city integrating functions such as R & D, incubation, production, logistics, administration and living. Biolake's six parks are expected to achieve total revenue of over RMB 200 billion yuan by 2018, thus becoming world-class bioindustry parks.
Print Collection Close
 Related News More>>
 Site Map | About Us | Services | Links | Statement

Ministry of Commerce of the People's Republic of China Department of Foreign Investment Administration

Operated by Investment Promotion Agency of MOFCOM

Tel:  (86-10) 64404554

Copyright by Invest in China

Fax: (86-10) 64515317

ICP Record No.: Beijing ICP 14022686-4 E-mail: service@fdi.gov.cn